Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Regulation of apoptosis proteins in cancer cells by ubiquitin


Ubiquitin inhibitors act at many levels to enhance apoptosis signaling. For TNF-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis signaling, there are at least five mechanisms by which apoptosis are regulated by the ubiquitin–proteasome pathway. First, proteasome inhibitors can decrease Fas-like inhibitor protein (FLIP) protein levels in tumors, resulting in increased apoptosis signaling due to increased caspase-8 activation. This appears to involve the ubiquitin ligase TNF receptor activation factor-2 (TRAF2) and acts indirectly by causing cell-cycle arrest at a stage where there is high degradation of the FLIP–TRAF2 complex. Second, the regulation of the proapoptotic Bcl-2 family member BAX occurs indirectly. Apoptosis signaling and caspase activation results in a confirmation change in the normally monomeric BAX, which exposes the BH3 domain of BAX, leading to dimerization and resistance to ubiquitin degradation. BAX then translocates into the mitochondria, resulting in the release of proapoptotic mitochondrial factors such as cytochrome c and second mitochondria-derived activator of caspase (SMAC). This results in the activation of caspase-9 and formation of the apoptosome and efficient apoptosis signaling. A third mechanism of the regulation of TRAIL signaling in the ubiquitin–proteasome pathway is mediated by the inhibitor of apoptosis proteins (IAP) E3 ligases. These IAPs can directly bind to caspases but also can act as ubiquitin ligases for caspases, resulting in the degradation of these caspases. IAP binding to caspases can be inhibited by SMAC, which exhibits a caspase-9 homology domain. The fourth mechanism for apoptosis activation by proteasome inhibitors is through the stabilization of the inhibitor of the κB (IκB)/NF-κB complex and prevention of nuclear translocation of the antiapoptosis transcription factor NF-κB. During TRAIL-DR4, DR5 signaling, this pathway is activated by interactions of activated Fas-associated death domain with activated receptor-interacting protein (RIP), which in turn activates NF-κB-inducing kinase and phosphorylates IκB. Therefore, the inhibition of IκB degradation blocks this RIP-mediated antiapoptosis signaling event. Last, p53 protein levels, and susceptibility to apoptosis, can be deregulated by the human homolog Hdm2 (Mdm2) E3 ligase. This process is inhibited by p53 phosphorylation and by sequestration of Mdm2 by ARF. Better mechanisms to inhibit the ubiquitin–proteasome pathway targeted at the ubiquitin–proteasome degradation process itself, or more specifically at the E3 ligases known to modulate and downregulate proapoptosis pathways will lead to the enhancement of TRAIL apoptosis signaling and better cancer therapeutic outcomes act through this pathway.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5


  • Argentini M, Barboule N and Wasylyk B . (2000). Oncogene, 19, 3849–3857.

  • Baetu TM and Hiscott J . (2002). Cytokine Growth Factor Rev., 13, 199–207.

  • Basu A and Haldar S . (2002). Int. J. Oncol., 21, 597–601.

  • Bodmer JL, Burns K, Schneider P, Hofmann K, Steiner V, Thome M, Bornand T, Hahne M, Schroter M, Becker K, Wilson A, French LE, Browning JL, MacDonald HR and Tschopp J . (1997). Immunity, 6, 79–88.

  • Bothner B, Lewis WS, DiGiammarino EL, Weber JD, Bothner SJ and Kriwacki RW . (2001). J. Mol. Biol., 314, 263–277.

  • Breitschopf K, Zeiher AM and Dimmeler S . (2000). J. Biol. Chem., 275, 21648–21652.

  • Brichese L, Barboule N, Heliez C and Valette A . (2002). Exp. Cell Res., 278, 101–111.

  • Brummerlkamp T, Nijman SB, Dirac AG and Bernards R . (2003). Nature, 424, 797–801.

  • Buschmann T, Fuchs SY, Lee CG, Pan ZQ and Ronai Z . (2000). Cell, 101, 753–762.

  • Chang YC, Lee YS, Tejima T, Tanaka K, Omura S, Heintz NH, Mitsui Y and Magae J . (1998). Cell Growth Differ., 9, 79–84.

  • de Rozieres S, Maya R, Oren M and Lozano G . (2000). Oncogene, 19, 1691–1697.

  • Dewson G, Snowden RT, Almond JB, Dyer MJ and Cohen GM . (2003). Oncogene, 22, 2643–2654.

  • Du C, Fang M, Li Y, Li L and Wang X . (2000). Cell, 102, 33–42.

  • Fukazawa T, Fujiwara T, Uno F, Teraishi F, Kadowaki Y, Itoshima T, Takata Y, Kagawa S, Roth JA, Tschopp J and Tanaka N . (2001). Oncogene, 20, 5225–5231.

  • Gottifredi V and Prives C . (2001). Science, 292, 1851–1852.

  • Gu J, Kawai H, Nie L, Kitao H, Wiederschain D, Jochemsen AG, Parant J, Lozano G and Yuan ZM . (2002). J. Biol. Chem., 277, 19251–19254.

  • Haas AL, Baboshina O, Williams B and Schwartz LM . (1995). J. Biol. Chem., 270, 9407–9412.

  • Haas AL and Siepmann TJ . (1997). FASEB J., 11, 1257–1268.

  • He H, Qi XM, Grossmann J and Distelhorst CW . (1998). J. Biol. Chem., 273, 25015–25019.

  • Holley CL, Olson MR, Colon-Ramos DA and Kornbluth S . (2002). Nat. Cell Biol., 4, 439–444.

  • Huang H, Joazeiro CA, Bonfoco E, Kamada S, Leverson JD and Hunter T . (2000). J. Biol. Chem., 275, 26661–26664.

  • Jesenberger V and Jentsch S . (2002). Nat. Rev. Mol. Cell. Biol., 3, 112–121.

  • Johnson TR, Stone K, Nikrad M, Yeh T, Zong WX, Thompson CB, Nesterov A and Kraft AS . (2003). Oncogene, 22, 4953–4963.

  • Kiechle FL and Zhang X . (2002). Clin. Chim. Acta, 326, 27–45.

  • Kim Y, Suh N, Sporn M and Reed JC . (2002). J. Biol. Chem., 277, 22320–22329.

  • Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D and Courtois G . (2003). Nature, 424, 801–805.

  • Leverkus M, Sprick MR, Wachter T, Mengling T, Baumann B, Serfling E, Brocker EB, Goebeler M, Neumann M and Walczak H . (2003). Mol. Cell. Biol., 23, 777–790.

  • Li B and Dou QP . (2000). Proc. Natl. Acad. Sci. USA, 97, 3850–3855.

  • Li M, Chen D, Shiloh A, Luo J, Nikolaev AY, Qin J and Gu W . (2002). Nature, 416, 648–653.

  • Liston P, Roy N, Tamai K, Lefebvre C, Baird S, Cherton-Horvat G, Farahani R, McLean M, Ikeda JE, MacKenzie A and Korneluk RG . (1996). Nature, 379, 349–353.

  • Liu Z, Sun C, Olejniczak ET, Meadows RP, Betz SF, Oost T, Herrmann J, Wu JC and Fesik SW . (2000). Nature, 408, 1004–1008.

  • MacFarlane M, Merrison W, Bratton SB and Cohen GM . (2002). J. Biol. Chem., 277, 36611–36616.

  • Martin SJ . (2002). Cell, 109, 793–796.

  • Martinou I, Missotten M, Fernandez PA, Sadoul R and Martinou JC . (1998). Neuroreport, 9, 15–19.

  • Olson MR, Holley CL, Yoo SJ, Huh JR, Hay BA and Kornbluth S . (2003). J. Biol. Chem., 278, 4028–4034.

  • Orian A, Whiteside S, Israel A, Stancovski I, Schwartz AL and Ciechanover A . (1995). J. Biol. Chem., 270, 21707–21714.

  • Park SJ, Kim YY, Ju JW, Han BG, Park SI and Park BJ . (2001). Biochem. Biophys. Res. Commun., 289, 1205–1210.

  • Rivera-Walsh I, Waterfield M, Xiao G, Fong A and Sun SC . (2001). J. Biol. Chem., 276, 40385–40388.

  • Rossi D and Gaidano G . (2003). Haematologica, 88, 212–218.

  • Sayers TJ, Brooks AD, Koh CY, Ma W, Seki N, Raziuddin A, Blazar BR, Zhang X, Elliott PJ and Murphy WJ . (2003). Blood, 102, 303–310.

  • Sengupta S, Vonesch JL, Waltzinger C, Zheng H and Wasylyk B . (2000). EMBO J., 19, 6051–6064.

  • Silke J, Verhagen AM, Ekert PG and Vaux DL . (2000). Cell. Death Differ., 7, 1275.

  • Srinivasula SM, Datta P, Fan XJ, Fernandes-Alnemri T, Huang Z and Alnemri ES . (2000). J. Biol. Chem., 275, 36152–36157.

  • Srinivasula SM, Hegde R, Saleh A, Datta P, Shiozaki E, Chai J, Lee RA, Robbins PD, Fernandes-Alnemri T, Shi Y and Alnemri ES . (2001). Nature, 410, 112–116.

  • Srivastava RK . (2001). Neoplasia, 3, 535–546.

  • Sudakin V, Ganoth D, Dahan A, Heller H, Hershko J, Luca FC, Ruderman JV and Hershko A . (1995). Mol. Cell. Biol., 6, 185–197.

  • Suzuki Y, Nakabayashi Y and Takahashi R . (2001). Proc. Natl. Acad. Sci. USA, 98, 8662–8667.

  • Suzuki M, Youle RJ and Tjandra N . (2000). Cell, 103, 645–654.

  • Takahashi R, Deveraux Q, Tamm I, Welsh K, Assa-Munt N, Salvesen GS and Reed JC . (1998). J. Biol. Chem., 273, 7787–7790.

  • Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A and Mosialos G . (2003). Nature, 424, 793–796.

  • Wang Q, Wang X and Evers BM . (2003). J. Biol. Chem..

  • Wesierska-Gadek J, Schloffer D, Kotala V and Horky M . (2002). Int. J. Cancer, 101, 128–136.

  • Wilson R, Goyal L, Ditzel M, Zachariou A, Baker DA, Agapite J, Steller H and Meier P . (2002). Nat. Cell Biol., 4, 445–450.

  • Wu JW, Cocina AE, Chai J, Hay BA and Shi Y . (2001). Mol. Cell, 8, 95–104.

  • Yang Y, Fang S, Jensen JP, Weissman AM and Ashwell JD . (2000). Science, 288, 874–877.

  • Yang YL and Li XM . (2000). Cell Res., 10, 169–177.

  • Zhou T, Mountz JD and Kimberly RP . (2002). Immunol. Res., 26, 323–336.

Download references


We thank Ms Carol Humber for excellent secretarial work. This work is supported by NIH Grants R01 AG 11653, N01, RO1 AI 42900 and CA 20408, a Birmingham VAMC Merit Review Grant, and a grant from Sankyo Inc. Huang-Ge Zhang is a recipient of Arthritis Foundation Investigator Award.

Author information

Authors and Affiliations


Corresponding author

Correspondence to John D Mountz.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Zhang, HG., Wang, J., Yang, X. et al. Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene 23, 2009–2015 (2004).

Download citation

  • Published:

  • Issue Date:

  • DOI:


  • cancer
  • apoptosis
  • ubiquitin proteasome inhibitor
  • BAX
  • NF-κB; p53
  • Mdm2

This article is cited by


Quick links